Erythropoietic protoporphyrias: updates and advances

Trends Mol Med. 2024 Sep;30(9):863-874. doi: 10.1016/j.molmed.2024.05.006. Epub 2024 Jun 17.

Abstract

Protoporphyrias are caused by pathogenic variants in genes encoding enzymes involved in heme biosynthesis. They induce the accumulation of a hydrophobic phototoxic compound, protoporphyrin (PPIX), in red blood cells (RBCs). PPIX is responsible for painful cutaneous photosensitivity, which severely impairs quality of life. Hepatic elimination of PPIX increases the risk of cholestatic liver disease, requiring lifelong monitoring. Treatment options are scarce and mainly limited to supportive care such as protection from visible light. Here, we review the pathophysiology of protoporphyrias, their diagnosis, and current recommendations for medical care. We discuss new therapeutic strategies, some of which are currently undergoing clinical trials and are likely to radically alter the severity of the disease in the years to come.

Keywords: cholestasis, intrahepatic; iron; protoporphyria, erythropoietic; protoporphyrin IX.

Publication types

  • Review

MeSH terms

  • Animals
  • Erythrocytes / metabolism
  • Heme / metabolism
  • Humans
  • Protoporphyria, Erythropoietic* / diagnosis
  • Protoporphyria, Erythropoietic* / genetics
  • Protoporphyria, Erythropoietic* / therapy
  • Protoporphyrins* / metabolism

Substances

  • Protoporphyrins
  • Heme
  • protoporphyrin IX